-
The FDA has approved the first drug for the treatment of Huntington's disease.
-
Whereas racial concordance is the primary predictor of perceived ethnic similarity, patients do value higher communication skills, which may actually result in better outcomes.
-
In knee OA, arthroscopic surgery confers no benefit.
-
Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
The ECG shown above was obtained from a patient who was seen in the office with atypical chest pain. Is there cause for concern?
-
Clinical trials of pharmacotherapy to prevent progression of cognitive decline in those with mild cognitive impairment (MCI) have been disappointing; neither cholinesterase inhibitors (donepezil, rivastigmine, galantamine), vitamin E, nor COX-2 inhibitors has demonstrated any clinically meaningful benefit in placebo-controlled MCI trials.
-
Estrogen treatment (but not estrogen given along with progestin) seems associated with gastro-esophageal reflux (GER) in postmenopausal women. Weight gain increases risk.
-
Lifestyle changes plus red yeast rice and fish oil resulted in similar beneficial effects on LDL cholesterol as moderate-dose statin therapy in patients meeting criteria for drug therapy for high LDL cholesterol.
-
Strategies to determine treatment of acute coronary syndromes need to take gender into account.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.